In the last trading session, 1.17 million shares of the X4 Pharmaceuticals Inc (NASDAQ:XFOR) were traded, and its beta was 0.48. Most recently the company’s share price was $0.29, and it changed around -$0.02 or -4.00% from the last close, which brings the market valuation of the company to $51.23M. XFOR currently trades at a discount to its 52-week high of $1.60, offering almost -451.72% off that amount. The share price’s 52-week low was $0.26, which indicates that the current value has risen by an impressive 10.34% since then. We note from X4 Pharmaceuticals Inc’s average daily trading volume that its 10-day average is 1.44 million shares, with the 3-month average coming to 3.67 million.
X4 Pharmaceuticals Inc stock received a consensus recommendation rating of Buy, based on a mean score of 1.00. If we narrow it down even further, the data shows that 0 out of 5 analysts rate the stock as a Sell; another 2 rate it as Overweight. Among the rest, 0 recommended XFOR as a Hold, whereas 3 deemed it a Buy, and 0 rated it as Underweight.
X4 Pharmaceuticals Inc (NASDAQ:XFOR) trade information
Instantly XFOR has showed a red trend with a performance of -4.00% at the end of last trading. The performance over the last five days has remained in the red territory. The rise to weekly highs of 0.3233 on recent trading dayincreased the stock’s daily price by 10.3%. The company’s shares are currently down -59.79% year-to-date, but still down -5.96% over the last five days. On the other hand, X4 Pharmaceuticals Inc (NASDAQ:XFOR) is -36.84% down in the 30-day period. We can see from the shorts that 9.48 million shares have been sold at a short interest cover period of 1.59 day(s).
The consensus price target as assigned by Wall Street analysts is $3, which translates to bulls needing to increase their stock price by 90.33% from its current value. Analyst projections state that XFOR is forecast to be at a low of $3 and a high of $5.
X4 Pharmaceuticals Inc (XFOR) estimates and forecasts
Looking at the company’s year-over-year earnings, the past five years showed a positive earnings growth rate of 73.95%. X4 Pharmaceuticals Inc earnings are expected to increase by 73.68% in 2025, but the outlook is positive 15.21% per year for the next five years.
X4 Pharmaceuticals Inc (NASDAQ:XFOR)’s Major holders
Upon looking at major shareholders, it appears that insiders hold 1.27% of X4 Pharmaceuticals Inc shares, and 59.20% of them are in the hands of institutional investors. The stock currently has a share float of 59.96%. X4 Pharmaceuticals Inc stock is held by 114.0 institutions, with BAIN CAPITAL LIFE SCIENCES INVESTORS, LLC being the largest institutional investor. By 2024-06-30, it held 8.4393% of the shares, which is about 16.92 million shares worth $9.81 million.
NEA MANAGEMENT COMPANY, LLC, with 7.4769% or 14.99 million shares worth $8.69 million as of 2024-06-30, holds the second largest percentage of outstanding shares.
Vanguard Total Stock Market Index Fund and iShares Russell 2000 ETF were the top two Mutual Funds as of Dec 31, 2024 . The former held 4.77 shares worth $1.41 million, making up 2.75% of all outstanding shares. On the other hand, iShares Russell 2000 ETF held roughly 4.4 shares worth around $1.3 million, which represents about 2.54% of the total shares outstanding.
